Mpox drug TPOXX put to the test in 328-Patient trial

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

This study has no age restriction Inclusion Criteria: 1. Laboratory-confirmed mpox infection as determined by PCR obtained from blood, oropharynx, or skin lesion within 48 hours of screening 2. Mpox illness of any duration provided that the patient has at least one active, not yet scabbed, lesion 3. Stated willingness to comply with all study procedures (including required inpatient stay) and availability for the duration of the study 4. Ability to provide informed consent personally or by a legally or culturally acceptable representative if the patient is unable to do so 5. Severe disease, defined as the presence of at least one of the following: 1. Flat lesions (flat and soft lesions; no pustules or vesicles visible to the eye) 2. Pregnancy (due to risk of serious complication) 3. Suspected sickle cell disease 4. Severe clinical disease, defined as having at least 3 of the following: * Lesion count greater than 250 * Fever for greater than 48 hours * Hypotension (systolic blood pressure less than 90 mmHg or diastolic blood pressure less than 60 mmHg) * Pallor * Respiratory distress * Altered mental status * Extreme lethargy * Painful oral lesions making oral intake difficult * Difficulty peeing or pooping due to painful lesions * Painful lesions on hands and feet * Tachycardia (heart rate greater than 100 beats per minute) * Diarrhea (greater than or equal to 3 liquid stools per 24 hours) Exclusion Criteria: 1. Severe anemia, defined as hemoglobin less than 7 g/dL 2. Current or planned use of another investigational drug at any point during study participation 3. Patients who, in the judgement of the investigator, will be at significantly increased risk as a result of participation in the study